Roth Capital analyst Boobalan Pachaiyappan recommends buying shares of Capricor Therapeutics (CAPR) on today’s selloff. The 8% pullback is a “transient, healthy and short-lived market correction” following the rally post FDA acceptance of Capricor’s application of deramiocel for the treatment of Duchenne muscular dystrophy, the analyst tells investors in a research note. Roth would be buying today’s “dislocation” and expects the share price to move towards its price target of $41. The firm has a Buy rating on Capricor.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
- Capricor Therapeutics price target raised to $63 from $50 at B. Riley
- Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
- Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)
- Capricor Therapeutics options imply 4.2% move in share price post-earnings